•   
  •   

Tech & Science Health Kick Podcast: How Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation

12:51  13 november  2019
12:51  13 november  2019 Source:   stockhead.com.au

Health Kick Podcast: The growth of musculoskeletal disorders, new markets created by ageing populations and OCC’s Avatar moment

  Health Kick Podcast: The growth of musculoskeletal disorders, new markets created by ageing populations and OCC’s Avatar moment Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne. Read More The post Health Kick Podcast: The growth of musculoskeletal disorders, new markets created by ageing populations and OCC’s Avatar moment appeared first on Stockhead.

You are currently logged into Cancer Health Directory - My Account or Log Out. Home. News. A novel drug that blocks multiple cancer -causing mutations shows promise, especially for How Much Do You Know About Cancer Risk? Only one in four Americans say they incorporate cancer

Introducing HealthKick A modern approach to a happy and healthy workforce. "I like how it' s a way for small companies to get some of the benefits that bigger companies have. It feels very personal, a lot of things that are happening right now in our neighborhood."

a man wearing a black shirt: Health Kick Podcast: How Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation© Stockhead Australia Health Kick Podcast: How Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation

Stockhead’s resident Health and Biotech expert Tim Boreham is coming to you live from the 2019 AusBiotech event in Melbourne.

In this episode Tim chats with Steven Yatomi-Clarke, CEO and managing director of Prescient Therapeutics (ASX:PTX).

Prescient Therapeutics is a Melbourne-based, clinical stage immune-oncology company that’s targeting specific mutations that cause cancers.

It’s got two candidates on the go, PTX 100 and PTX 200 and they both have novel mechanisms of action.

Hot tips from Aussie small cap tech stocks that have actually broken into the US market

  Hot tips from Aussie small cap tech stocks that have actually broken into the US market It is a battle to break into any market, but for small cap tech plays the US can be particularly Read More The post Hot tips from Aussie small cap tech stocks that have actually broken into the US market appeared first on Stockhead.

Tested natural health products made from premium eco-friendly materials. This is the unlikely story of how three friends from Australia set out to build a health company with one focus: the gut. Several years ago, our mums battled and survived cancer .

HLTH (pronounced “ health ”) is a one-of-a-kind ecosystem event for the health industry, and we ’ re on a mission to bring together 7,000+ senior leaders to solve the most pressing problems facing healthcare today and actualize the most promising opportunities to improve health .

In particular, Prescient is targeting a mutant pathway called Ras, which has been difficult to access with traditional cancer therapies.

So tune in to hear the pair discuss Australia’s biotech performance on how Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation.

On mobile? Click here to listen with Apple podcasts, here for Spotify or here for Google Podcasts.

Like to listen to podcasts through another app? Just search for The Health Kick Podcast with Tim Boreham and subscribe!

The post Health Kick Podcast: How Aussie health stocks are performing internationally and Prescient’s cancer-blocking innovation appeared first on Stockhead.

World-first trial to target and kill cancer cells brings hope to cancer patients .
Adelaide doctors believe they have made a major breakthrough in cancer treatment, and will conduct clinical trials of a new technology to find, and hopefully destroy, cancer cells. The treatment — developed by clinical teams at the Royal Adelaide Hospital (RAH) — has secured $33 million in funding to move to human trials, after researchers had success treating mice suffering with lymphoma.Head of RAH's cancer clinical trials unit, Professor Michael Brown, said the new technique would use antibodies that carry a low dose of radiation to target dead or dying cancer cells.

—   Share news in the SOC. Networks
usr: 3
This is interesting!